Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Zimberelimab in Recurrent/Metastatic Cervical, Vulvar, and Vaginal Cancer
NCT07424664Phase 2Recruiting
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin in Cervical Cancer (CC), vulvar cancer and vaginal cancer. Primary endpoint: Objective Response Rate at 36 months. Started Jun 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
Cervical Cancer (CC)vulvar cancervaginal cancer
Beyond the preview
Go deeper on NCT07424664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07424664.